MedTrace Logo

Inhaled Milrinone in Cardiac Surgery

NCT01725776 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-11-14

No results posted yet for this study

Summary

The purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Inhaled milrinone 5 mg

Inhaled milrinone 5 mg (as for the injectable solution)

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Fonds de la Recherche en Santé du Québec

    collaborator OTHER_GOV

  • St. Justine's Hospital

    collaborator OTHER

  • Montreal Heart Institute

    lead OTHER

Principal Investigators

  • Andrée Denault, MD PhD FRCPC · Montreal Heart Institute

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2012-02-29
Completion
2012-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01725776 on ClinicalTrials.gov